Clinical Significance of Circulating Tumor Cells in Patients with Esophageal Cancer

Overview

Journal Juntendo Iji Zasshi

Specialty General Medicine

Date 2024 Jul 18

PMID 39021432

Authors

Hiromi Kitano

Motomi Nasu

Takashi Hashimoto

Masahiko Tsurumaru

Yoshiaki Kajiyama

Affiliations

Soon will be listed here.

Abstract

Objective: In recent years, circulating tumor cells (CTCs) have attracted attention for prediction of metastasis in breast, prostate, and colon cancers. This study aimed to investigate whether detection of CTCs could be prognostic factor in esophageal cancer.

Methods: This study involved 38 patients treated at Juntendo University from May 2010 to April 2013 who provided consent. CTCs were measured using CellSearch system in preoperative peripheral blood. Clinicopathological parameters and prognostic factors were retrieved from our medical records.

Results: CTCs were detected in 6 of 38 patients (15.8%). Among patients' characteristics and clinicopathological features, CTC-positive group had higher serum SCC levels and tended to have more advanced cStages than the CTC-negative group. The CTC-negative group showed better survival curves than CTCs positive-group in both overall survival (OS) and disease-free survival (DFS) although the differences were not statistically significant. CTCs positivity has a possibility to be prognostic marker according to multivariable analysis of OS and DFS.

Conclusion: Although this study has some limitations, our results suggest that CTCs in preoperative peripheral blood has potential to be a prognostic marker for esophageal cancer.

References

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20(7):1223-9. DOI: 10.1093/annonc/mdn786. View

Mei X, Zhu X, Zuo L, Wu H, Guo M, Liu C . Predictive significance of CYFRA21-1, squamous cell carcinoma antigen and carcinoembryonic antigen for lymph node metastasis in patients with esophageal squamous cancer. Int J Biol Markers. 2019; 34(2):200-204. DOI: 10.1177/1724600819847999. View

Watanabe M, Toh Y, Ishihara R, Kono K, Matsubara H, Murakami K . Comprehensive registry of esophageal cancer in Japan, 2014. Esophagus. 2021; 19(1):1-26. PMC: 8738507. DOI: 10.1007/s10388-021-00879-1. View

Lurje G, Schiesser M, Claudius A, Schneider P . Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J Oncol. 2009; 2010:392652. PMC: 2774472. DOI: 10.1155/2010/392652. View

Tarumi S, Gotoh M, Kasai Y, Matsuura N, Okuda M, Go T . Innovative method using circulating tumor cells for prediction of the effects of induction therapy on locally advanced non-small cell lung cancer. J Cardiothorac Surg. 2013; 8:175. PMC: 3718657. DOI: 10.1186/1749-8090-8-175. View

Tol J, Koopman M, Miller M, Tibbe A, Cats A, Creemers G . Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2009; 21(5):1006-12. DOI: 10.1093/annonc/mdp463. View

Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N . Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2009; 17(3):199-204. DOI: 10.1007/s12282-009-0139-3. View

Coumans F, Ligthart S, Terstappen L . Interpretation of changes in circulating tumor cell counts. Transl Oncol. 2013; 5(6):486-91. PMC: 3542841. DOI: 10.1593/tlo.12247. View

Miller M, Doyle G, Terstappen L . Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2009; 2010:617421. PMC: 2793426. DOI: 10.1155/2010/617421. View

10.

Hashimoto T, Kajiyama Y, Tsutsumi-Ishii Y, Nagaoka I, Tsurumaru M . Circulating micrometastases of esophageal cancer detected by carcinoembryonic antigen mRNA reverse transcriptase-polymerase chain reaction: clinical implications. Dis Esophagus. 2008; 21(8):690-6. DOI: 10.1111/j.1442-2050.2008.00830.x. View

11.

Qian H, Zhang Y, Xu J, He J, Gao W . Progress and application of circulating tumor cells in non-small cell lung cancer. Mol Ther Oncolytics. 2021; 22:72-84. PMC: 8408556. DOI: 10.1016/j.omto.2021.05.005. View

12.

Turato C, Scarpa M, Kotsafti A, Cappon A, Quarta S, Biasiolo A . Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. Cancer Sci. 2019; 110(5):1552-1563. PMC: 6501024. DOI: 10.1111/cas.13986. View

13.

Okegawa T, Nutahara K, Higashihara E . Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol. 2010; 17(5):466-75. DOI: 10.1111/j.1442-2042.2010.02502.x. View

14.

Matsusaka S, Chin K, Ogura M, Suenaga M, Shinozaki E, Mishima Y . Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010; 101(4):1067-71. PMC: 11159155. DOI: 10.1111/j.1349-7006.2010.01492.x. View

15.

Togo S, Katagiri N, Namba Y, Tulafu M, Nagahama K, Kadoya K . Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients. Oncotarget. 2017; 8(21):34884-34895. PMC: 5471019. DOI: 10.18632/oncotarget.16818. View